Cargando…

Use of lipid-lowering agents is not associated with improved outcomes for tuberculosis patients on standard-course therapy: A population-based cohort study

OBJECTIVES: Animal and ex vitro studies suggested lipid-lowering agents (LLAs) may be used as an adjunct to standard anti- tuberculosis (TB) treatment. No human study has been conducted to date. Using the Taiwan National Health Insurance Research Database (NHIRD), the current population-based cohort...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yung-Tai, Kuo, Shu-Chen, Chao, Pei-Wen, Chang, Yea-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329498/ https://www.ncbi.nlm.nih.gov/pubmed/30633771 http://dx.doi.org/10.1371/journal.pone.0210479

Ejemplares similares

Clinical and economic impact of intensive care unit-acquired bloodstream infections in Taiwan: a nationwide population-based retrospective cohort study
por: Wang, Yung-Chih, et al.
Publicado: (2020)

Novel Uses for Lipid-Lowering Agents
por: May, Megan Brafford, et al.
Publicado: (2016)

Influenza vaccination and secondary prevention of cardiovascular disease among Taiwanese elders—A propensity score-matched follow-up study
por: Wu, Hao-Hsin, et al.
Publicado: (2019)

Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study
por: Tao, Heqing, et al.
Publicado: (2023)

The Protective Effects of Lipid-Lowering Agents on Cardiovascular Disease and Mortality in Maintenance Dialysis Patients: Propensity Score Analysis of a Population-Based Cohort Study
por: Tsai, Ming-Hsien, et al.
Publicado: (2022)

Risk of Herpes Zoster in Patients with Pulmonary Tuberculosis—A Population-Based Cohort Study
por: Wang, Chih-An, et al.
Publicado: (2023)

Role of lipid-lowering agents in the management of diabetic retinopathy
por: Ioannidou, Estelle, et al.
Publicado: (2017)

Formulation and Evaluation of Nanocrystals of a Lipid Lowering Agent
por: Louis, Dina
Publicado: (2016)

Statins and the Brain: More than Lipid Lowering Agents?
por: Fracassi, Anna, et al.
Publicado: (2019)

Judicious Use of Lipid Lowering Agents in the Management of NAFLD
por: Iqbal, Umair, et al.
Publicado: (2018)

Corrigendum: The Protective Effects of Lipid-Lowering Agents on Cardiovascular Disease and Mortality in Maintenance Dialysis Patients: Propensity Score Analysis of a Population-Based Cohort Study
por: Tsai, Ming-Hsien, et al.
Publicado: (2022)

Lipid-lowering agents for dyslipidemia in patients who were infected with HIV in Taoyuan, Taiwan
por: Cheng, Shu-Hsing, et al.
Publicado: (2014)

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients: A Nationwide Population-Based Cohort Study
por: Chien, Shu-Chen, et al.
Publicado: (2015)

Successful Treatment of Xanthoma Disseminatum with Combined Lipid Lowering Agents
por: Kim, Won-Jeong, et al.
Publicado: (2012)

Garlic as a Lipid Lowering Agent—A Meta-Analysis
por: Silagy, Christopher, et al.
Publicado: (1994)

Discovery of 7,9-Disulfatetrahydroberberine as Novel Lipid-Lowering Agents
por: Li, Dong-Dong, et al.
Publicado: (2020)

Persistence With Lipid-Lowering Therapy: Influence of the Type of Lipid-Lowering Agent and Drug Benefit Plan Option in Elderly Patients
por: Abughosh, Susan M., et al.
Publicado: (2004)

Association between lipid-lowering agents and severe hyponatremia: a population-based case–control study
por: Skov, Jakob, et al.
Publicado: (2020)

Barriers in utilizing lipid-lowering agents in non-institutionalized population in the U.S.: Application of a theoretical framework
por: Alfaifi, Abdullah A., et al.
Publicado: (2021)

What’s Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2019)

Osteoporosis increases subsequent risk of gallstone: a nationwide population-based cohort study in Taiwan
por: Klahan, Sukhontip, et al.
Publicado: (2014)

Acid suppressive agents and risk of Mycobacterium Tuberculosis: case–control study
por: Hsu, Wen-Hung, et al.
Publicado: (2014)

Association between lipid variability and the risk of mortality in cancer patients not receiving lipid-lowering agents
por: Kim, Seohyun, et al.
Publicado: (2023)

Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo.
por: Mulligan, H. D., et al.
Publicado: (1991)

Long‐Term Risk of Cardiovascular Events in Patients With Chronic Kidney Disease Who Have Survived Sepsis: A Nationwide Cohort Study
por: Shih, Chia‐Jen, et al.
Publicado: (2017)

Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study
por: Lee, Meng-Rui, et al.
Publicado: (2019)

Standard course : HSK 3 /

Standard Course : HSK 1 /

Standard course : HSK 2 /

The Standard Model: course
por: Pich, A
Publicado: (2006)

The Standard Model: course
por: Pich, A
Publicado: (2007)

Standard course : HSK 1 workbook /

Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008
por: Kuznik, Andreas, et al.
Publicado: (2011)

Is there lower utilisation of hospice care services during end-of-life care for people living with HIV? A population-based cohort study
por: Chan, Shang-Yih, et al.
Publicado: (2022)

Epidemiological Characteristics of Lower Extremity Cellulitis after a Typhoon Flood
por: Lin, Pei-Chen, et al.
Publicado: (2013)

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
por: Kim, Kyuho, et al.
Publicado: (2022)

Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging
por: Di Giovanni, Giuseppe, et al.
Publicado: (2022)

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
por: Kim, Kyuho, et al.
Publicado: (2022)

The effect of pay for performance on risk incidence of hip fracture in type 2 diabetic patients: a nationwide population-based cohort study
por: Lee, Yung-Heng, et al.
Publicado: (2020)

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
por: Yang, Chun-Ting, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ojqliknpog7bj8vd6dct3b6scu